Drug interactions
Bosentan + Linagliptin-metformin
Severity: Minor
Bosentan and Linagliptin-metformin: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Bosentan is a CYP3A4 inducer and may lower linagliptin exposure, potentially reducing glucose-lowering effect. The magnitude is probably modest because linagliptin is mostly eliminated unchanged.
What this interaction means in plain words
Bosentan and Linagliptin-metformin have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Bosentan belongs to Miscellaneous; Linagliptin-metformin belongs to Endocrine.
Why it happens
Induction of CYP3A4 (and possibly P-gp) increases metabolism and clearance of linagliptin.
What to do
Monitor glycemic control after starting or stopping bosentan and adjust antidiabetic therapy if control worsens.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Bosentan and Linagliptin-metformin, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Linagliptin-metformin
Other interactions of Bosentan
- Bosentan + Cyclosporin Contraindicated
- Bosentan + Glibenclamide Contraindicated
- Bosentan + Glyburide-metformin Contraindicated
- Bosentan + Lonafarnib Contraindicated
- Bosentan + Sparsentan Contraindicated
- Artemether / lumefantrine + Bosentan Major
Frequently asked questions
Can I take Bosentan with Linagliptin-metformin?
MediHelp rates the interaction as minor. Bosentan and Linagliptin-metformin have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Bosentan is a CYP3A4 inducer and may lower linagliptin exposure, potentially reducing glucose-lowering effect. The magnitude is probably modest because linagliptin is mostly eliminated unchanged.
How serious is the interaction between Bosentan and Linagliptin-metformin?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor glycemic control after starting or stopping bosentan and adjust antidiabetic therapy if control worsens.
What other medicines interact with Linagliptin-metformin?
MediHelp also lists interactions of Linagliptin-metformin with, for example, Apalutamide, Carbamazepine, Contrast media. The full list is on the Linagliptin-metformin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
